2 registrations that name fenugreek as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
All 2 registrations
Not yet recruitingNCT06826716
A Study to Assess the Effect of Libifem® (VL-GF-01) on Fertility in Women With Diminished Ovarian Reserve
No phase
Vedic Lifesciences Pvt. Ltd.
About 150 people
Starts Feb 10, 2025 (estimated)
In plain words A study of fenugreek in female participants 25 to 35, run by Vedic Lifesciences Pvt. Ltd.. It plans to enroll about 150 people at 7 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 25 to 35. Conditions: Female Fertility.
Individuals ready to give voluntary, written informed consent to participate in the study.
Women of age between 25 to 35 years who wish to conceive.
Women with BMI between 18.5 to 34.9 kg/m2 (both values included).
Women who are unable to conceive for at least one year with an unprotected sexual life.
10 more inclusion criteria and the exclusion criteria are on the listing.
The present study is a randomized, double-blind, placebo-controlled, parallel clinical study. Approximately 156 participants will be screened, and considering a screening failure rate of 20%, not more than 124 participants will be randomized in a ratio of 1:1 to receive either Libifem® or placebo and will be assigned a unique randomization code. Each group will have not less than 50 completed participants after accounting for a dropout/withdrawal rate of 20%.
Where, as registered
No US site; India (7).
Not yet recruitingNCT07056712
Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
No phase
University of Guadalajara
About 28 people
Starts Sep 15, 2025 (estimated)
In plain words A study of fenugreek in people 30 to 60, run by University of Guadalajara. It plans to enroll about 28 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 60. Conditions: Metabolic Syndrome.
Men and women between 30 and 60 years old.
Diagnosis of Metabolic Syndrome (MS) according to the International Diabetes Federation (IDF) criteria.
Fasting glucose ≥100 mg/dL or previous diagnosis of type 2 diabetes.
Systolic Blood Pressure ≥130 mmHg.
17 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Fenugreek seed; Placebo
Registered summary
Fenugreek has been shown to have beneficial effects on various metabolic abnormalities associated with metabolic syndrome (MS). However, no clinical trials have evaluated its effect on all components of MS, insulin sensitivity, and insulin secretion. Therefore, the main objective of this study is to assess the effect of fenugreek seed administration versus placebo on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.